| Bioactivity | BF-168, a candidate probe for PET, is found to specifically recognize both neuritic and diffuse plaques, with a Ki of 6.4 nM for Aβ1-42. | ||||||
| Target | Ki: 6.4 nM (Aβ1-42). | ||||||
| Invitro | BF-168, a styrylbenzoxazole derivative, is a potent agent that selectively recognizes SPs and NFTs in AD brain. BF-168 is a candidate probe for PET and is found to specifically recognize both neuritic and diffuse plaques, with a Ki of 6.4 nM for Aβ1-42[1]. | ||||||
| In Vivo | Intravenous injection of BF-168 in PS1/APP and APP23 transgenic mice result in specific in vivo labeling to both compact and diffuse amyloid deposits in the brain. In addition, 18F-radiolabeled BF-168 demonstrates abundant initial brain uptake (3.9% injected dose/gm at 2 min after injection) and fast clearance (t1/2=24.7 min) after intravenous administration in normal mice. Furthermore, autoradiograms of brain sections from APP23 transgenic mice at 180 min after intravenous injection of [18F]BF-168 shows selective labeling of brain amyloid deposits with little nonspecific binding[1]. | ||||||
| Name | BF-168 | ||||||
| CAS | 634911-47-0 | ||||||
| Formula | C18H17FN2O2 | ||||||
| Molar Mass | 312.34 | ||||||
| Appearance | Solid | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage |
*该产品在溶液状态不稳定，建议您现用现配，即刻使用。 |
||||||
| Reference | [1]. Okamura N, et al. Styrylbenzoxazole derivatives for in vivo imaging of amyloid plaques in the brain. J Neurosci. 2004 Mar 10;24(10):2535-41. |
BF-168
CAS: 634911-47-0 F: C18H17FN2O2 W: 312.34
BF-168, a candidate probe for PET, is found to specifically recognize both neuritic and diffuse plaques, with a Ki of 6.
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.